{"entity":{"id":"nct07079475","kind":"trial","name":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","aka":["TIAN-SHAN8"],"tldr":"A phase 1/2 trial of Sunvozertinib, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.","summary":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) is a phase 1/2 interventional study registered as NCT07079475 by Dizal Pharmaceuticals, with 220 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-06. Interventions recorded: DZD6008, Sunvozertinib, Osimertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07079475","url":"https://clinicaltrials.gov/study/NCT07079475"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["sunvozertinib","osimertinib"],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07079475","phase":"1/2","setting":"A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combined With Sunvozertinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN8)","sponsor":"Dizal Pharmaceuticals","participation":[{"nct":"NCT07079475","source":"https://clinicaltrials.gov/study/NCT07079475","fetchedAt":"2026-10-07T16:55:25.997Z","studySha256":"73e055f8c4e30fd8042e921eba3ddbfabf13812be4ee774677e51ce56dddbcfb","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-31","leadSponsor":"Dizal Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":220,"enrolmentType":"ESTIMATED","siteCount":16,"recruitingSiteCount":9,"countries":["China"]}],"started":"2025-07-30","startedType":"actual","enrolled":220,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07079475/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}]}}